KRAKOW, Poland, May 29, 2025 / Biotech Newswire / -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, today announced the promotion of Justyna Żółtek, Chief People Officer, to its Management Board.
“We are excited to promote Justyna to the Management Board of Ryvu,” said Piotr Romanowski, President of Ryvu Therapeutics Supervisory Board. “Justyna has been instrumental in establishing an organization and culture that allows Ryvu to advance its scientific and business goals. Her promotion comes at a critical juncture in Ryvu’s evolution in a dynamic external and internal environment, and we are confident in her ability to help lead and navigate Ryvu to the next phase.”
Ms. Żółtek joined Ryvu in 2021, taking on the strategic challenge of establishing the HR function from the ground up during a key phase of the company’s growth and organizational development. Over the following five years, she designed and implemented a comprehensive people strategy, built the HR team, and introduced core processes supporting leadership development, talent management, and culture transformation. Her work has been instrumental in helping Ryvu scale as a fast-moving biotech company, not only by supporting its growth but also by successfully leading critical organizational changes — all while ensuring that both transformation and expansion remain deeply rooted in the company’s values and its people.
Ms. Żółtek commented, “Breakthrough discoveries require many resources – one of the most important is talent: ambitious, motivated and collaborative scientists. At Ryvu, we have always been aware of this and have consistently developed team players and management. Strengthening the Management Board with competencies in this field is a natural step and another investment in the long-term value of the company.”
Justyna brings over 15 years of experience from international organizations, having held cross-country HR roles in industries such as biotechnology, energy, construction, and technology. She specializes in driving organizational transformation and building HR structures in companies scaling from early growth to operational excellence. Her approach combines strategic thinking with practical execution in fast-paced, evolving business environments.
She holds a degree from the Cracow University of Economics and is a graduate of the prestigious Center for Leadership program — one of Poland’s most respected leadership development initiatives for business executives.
About Ryvu Therapeutics
Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel oncology therapies that address emerging targets in oncology. Internally discovered pipeline candidates at Ryvu use diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules and antibody-drug conjugates directed at kinases, synthetic lethality, and immuno-oncology targets.
Ryvu’s most advanced program is RVU120, a selective CDK8/CDK19 kinase inhibitor with the potential to treat hematological malignancies. RVU120 is currently in Phase II development (i) in combination with venetoclax for the treatment of patients with r/r AML – the RIVER-81 study, (ii) as a monotherapy for the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) – the REMARK study, (iii) as a monotherapy and in combination with ruxolitinib for the treatment of patients with myelofibrosis (MF) – the POTAMI-61 study. Dapolsertib (MEN1703, SEL24) is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is currently being investigated in a Phase II study in diffuse large B-cell lymphoma (DLBCL) – the JASPIS-01 study. RVU305, a potentially best-in-class, brain-permeable PRMT5 inhibitor aiming to treat multiple solid tumors, is currently in IND/CTA-enabling studies. Ryvu Therapeutics is also engaged in oncology collaborations with e.g. BioNTech and Exelixis.
Ryvu was founded in 2007 and is headquartered in Kraków, Poland. It is listed on the Warsaw Stock Exchange and is a component of the sWIG80 index.
Contact
Ryvu Therapeutics
Anna Wilk
+48 532 698 425
This email address is being protected from spambots. You need JavaScript enabled to view it.
Source: Biotech Newswire